Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 9/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27706924 | 0.84 | ACKR3 (0.40) | LMNAACKR3TMEM97SIGMAR1NPC1 | |
| SCHEMBL3574958 | 0.77 | SCD (0.69) | SCDLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3582089 | 0.77 | SCD (0.56) | SCDLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4194371 | 0.73 | SCD (0.59) | SCDNPC1 | |
| SCHEMBL3587287 | 0.73 | SCD (0.65) | SCDLMNANPC1RAB9AHTT | |
| SCHEMBL5230740 | 0.72 | HDAC6 (0.72) | LMNANPC1RAB9A | |
| SCHEMBL3578661 | 0.69 | SCD (0.66) | SCDLMNANPC1RAB9AHTT | |
| SCHEMBL244641 | 0.69 | SCD (0.58) | SCDLMNAHTTSMN1; SMN2PPARA | |
| SCHEMBL243885 | 0.69 | SCD (0.65) | SCDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3583154 | 0.69 | SCD (0.76) | SCDLMNANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541457-B2 | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2013-09-24 | — | — | US | disclosed |
| US-20130096056-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| EP-2540296-A1 | Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2013-01-02 | — | — | EP | disclosed |
| US-20100152187-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-17 | — | — | US | disclosed |
| EP-2029138-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007130075-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152187-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, ACAT1 | SCD 1/4885LMNA 1423/4885ACKR3 2660/4885 |
| US-20130096056-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, ACAT1 | SCD 1/4885LMNA 1399/4885ACKR3 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.